Proudly sponsored by: Lotus Clinical Research and MD Biosciences
The global opioids market size was valued at $22.96bn USD in 2016 and is projected to expand at a CAGR of 4.8% between 2018 and 2025. Rising prevalence of diseases that cause chronic pain, such as cancer, lower back pain, post-surgical pain, arthritis, and fibromyalgia, is driving growth.
Join Europe's leading Pain Therapeutics Conference, to explore the cutting-edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.
The 19th annual conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, atypical opioids, migraine treatments, such as Lasmiditan and Aimovig, novel discoveries in opioid-free analgesia and the future forecast for pain therapeutics – industry leaders will uncover the latest advancements in the field. Furthermore, policy experts will provide an essential regulatory perspective for this year’s agenda, providing an exciting and comprehensive insight into the pain therapeutics market.
New case studies and regulatory perspectives will bring together the challenges and successes of both pre-clinical and clinical development to equip you with the necessary knowledge to advance the pain therapeutic industry.
Event Hashtag: #SMiPainTherapeutics
WHO SHOULD ATTEND
Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:
Pain and Migraine
Inflammation
Chronic Pain
Neuropathic Pain
Analgesic pre-clinical development
Anaesthesia and Pain Management
CNS clinical trials
Ion Channel Pharmacology
Pharmacology Intelligence
Translational science
Drug development
Exploratory development
EARLY BIRD-RATES
• BOOK BY 28TH FEBRUARY AND SAVE £200
• BOOK BY 29TH MARCH AND SAVE £100
